BPC-157 vs TB-500: What the Research Shows
BPC-157 and TB-500 side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider BPC-157 if…
- you want any human reports (a small, uncontrolled report): 14 of 16 patients (87.5%) reported relief with BPC 157 alone or combined with thymosin beta-4 (TB4).[24]
Consider TB-500 if…
- you are weighing animal data: the only study of TB-500 itself in our review is in rats, where higher maximum load to failure in the Achilles tendon reached significance for TB-500 (p < 0.05)[8]
What they have in common
Spec comparison
Showing 8 of 12 fields where the two differ. Category, FDA status, PCAC vote, Jul 2026, Vial sizes sold are the same or both unknown.
| Field | BPC-157 | TB-500 |
|---|---|---|
| Class | Gastric pentadecapeptide | Synthetic fragment of thymosin beta-4 |
| Also called | BPC, body protection compound, Pentadecapeptide BPC 157 | TB4, thymosin beta-4, TB-500 fragment |
| Category | Healing & recovery | Healing & recovery |
| FDA status | PCAC voted 8–6 for 503A (Jul 2026) | PCAC voted 8–6 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized | PCAC voted 8–6 for the 503A list (Jul 2026); not finalized |
| WADA | Prohibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition. | Prohibited by WADA (S2.3)TB-500 is named as a thymosin-beta-4 derivative in S2.3 (growth factors), prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | less than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143 | Human RCT evidence, 4 of 4Strongest: Cardiovascular research 2025, PMID 41229390 |
| Human studies we summarised | 3 human (0 randomized or controlled) of 25 summarised | 7 human (7 randomized or controlled) of 16 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 10 mg, 20 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Sold mixed: KLOW, GLOW, Wolverine
These blends put both in one vial. The blend calculator works out the dose of each component per draw. Evidence for the combination: 1 published study included both (PMID 42542926).
The one direct comparison is a rat tendon study
Only one study we found puts both peptides in one experiment. It was in rats, not people, and tested each peptide alone and together on Achilles tendon healing.[8]
In that rat experiment, the combination did no better than either peptide alone.[8]
The tendon-strength result split the two peptides in rats: both groups were numerically above controls, but only the TB-500 group reached statistical significance on maximum load to failure.[8]
On tendon histology in the same rat study, the BPC-157 group showed numerically lower scores without a significant difference in total score.[8]
What each peptide's studies actually measured
BPC-157's human reports are small uncontrolled clinic series: a knee-pain chart review, a bladder-pain pilot and an intravenous safety pilot. The knee series pooled patients who got BPC-157 alone with those who also got TB4, so it cannot separate the two.[24]
A bladder pilot of BPC-157 in 12 patients with interstitial cystitis reports complete symptom resolution in 10 of them. It had no control group.[7]
A pilot of intravenous BPC-157 reports no measurable change in the heart, liver, kidney, thyroid or blood glucose markers it tested. It was a safety pilot, not an efficacy study.[6]
TB-500 is a synthetic fragment of thymosin beta-4, and the human trials sit on the parent molecule rather than on TB-500 itself. A randomized placebo-controlled dose study of intravenous thymosin beta-4 in healthy volunteers found it well tolerated across a wide range.[23]
Thymosin beta-4 was also tested in a 73-patient phase 2 venous ulcer trial, applied topically, where the authors say a 0.03% dose may have potential to accelerate wound healing.[28]
Not every thymosin beta-4 trial was positive. In a dry eye trial, neither primary endpoint differed significantly between treatment and control.[29]
In a heart-attack trial of recombinant thymosin beta-4, the overall difference in infarct area versus placebo was not significant.[11]
Route, kinetics and detection: how they differ in practice
BPC-157's animal pharmacokinetic study (rats and beagle dogs) found an elimination half-life of under 30 minutes after intravenous or intramuscular dosing.[5]
The same study measured intramuscular bioavailability of BPC157 at roughly 14%-19% in rats and 45%-51% in beagle dogs, so absorption differed by species and cannot be assumed for people.[5]
For TB-500, the pharmacology we found is an anti-doping method in horses: after a single dose, TB-500 and its metabolites were detected in equine urine and plasma. It says nothing about human dosing.[9]
BPC-157 has no US drug-approval record: the FDA Drugs@FDA search for it returned no matches.[30]
TB-500 has no record either: its Drugs@FDA search also found no matches.[31]
Common questions
BPC-157 vs TB-500: which is better?
No study in people compares them. The only head-to-head is a rat tendon study, where only the TB-500 group reached significance on maximum load to failure.[8]
Can you take BPC-157 and TB-500 together?
The only combination data are from rats, where the pair gave no added benefit over either alone. We found no human combination trial.[8]
Is TB-500 the same as thymosin beta-4?
Not exactly. TB-500 is described as a synthetic version of an active region of thymosin beta-4, so trials of full thymosin beta-4 do not directly prove anything about TB-500.[9]
Which has more human evidence, BPC-157 or TB-500?
Neither has strong human evidence for the use people ask about. BPC-157 has a few small uncontrolled reports; thymosin beta-4 has randomized trials, but in wound, eye and heart settings and on the parent molecule.[24]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
- 4Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
- 5Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
- 6Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
- 7Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
- 8Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
- 9Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry.Journal of chromatography. A · 2012PMID 23084823Accessed 2 Oct 2026
- 10Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
- 11Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion.Cardiovascular research · 2025PMID 41229390Accessed 2 Oct 2026
- 12A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers.Journal of cellular and molecular medicine · 2021PMID 34346165Accessed 2 Oct 2026
- 13Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis.Microbial biotechnology · 2021PMID 34318587Accessed 2 Oct 2026
- 14Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 15PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) (1199 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (humans[mh] OR patients[tiab]) (678 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (randomized[tiab] OR clinical trial[pt]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 18PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 19PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (wound[tiab] OR dermal[tiab] OR skin[tiab] OR hair[tiab]) (212 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 20PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab]) AND (tendon[tiab] OR muscle[tiab] OR cardiac[tiab] OR myocardial[tiab] OR heart[tiab]) (246 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 21PubMed search: "TB-500"[tiab] OR TB500[tiab] OR "Ac-LKKTETQ"[tiab] (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 22PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 23A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers.Annals of the New York Academy of Sciences · 2010PMID 20536472Accessed 2 Oct 2026
- 24Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain.Alternative therapies in health and medicine · 2021PMID 34324435Accessed 2 Oct 2026
- 25Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 26PubMed search: ("TB-500"[tiab] OR TB500[tiab] OR "thymosin beta-4"[tiab] OR "thymosin beta4"[tiab] OR Tbeta4[tiab] OR RGN-259[tiab] OR RGN-137[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (61 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 27PubMed search: ("RGN-259"[tiab] OR "RGN-137"[tiab] OR "thymosin beta 4"[tiab]) AND (eye[tiab] OR ophthalmic[tiab] OR neurotrophic[tiab] OR cornea*[tiab]) AND (patients[tiab] OR trial[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 28The effect of thymosin treatment of venous ulcers.Annals of the New York Academy of Sciences · 2010PMID 20536470Accessed 2 Oct 2026
- 29Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 30Drugs@FDA (openFDA) search: active ingredient "BPC-157"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 31Drugs@FDA (openFDA) search: active ingredient "TB-500"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.